TrialTrials2024

HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.

Budhi Singh Yadav et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.